Nature's Bioceuticals Consummates Purchase of Diabetes Formula

CAPE CORAL, Fla., Nov. 15, 2011 /PRNewswire/ -- Nature's Bioceuticals, a wholly owned subsidiary of Mistral Ventures Inc. (MILV.pk) is please to announce that it has consummated the purchase of the diabetes formula and now holds the exclusive rights. At the request of the inventor, to protect his privacy, financial terms are not to be disclosed in press releases.

According to the New Diabetes Atlas figures released on 9/13/2011 by The International Diabetes Federation (IDF) the number of people with diabetes in 2011 has reached a staggering 366 million,  , 4.6 million deaths are due to diabetes and health care spending on diabetes has reached 465 billion USD. The number is expected to grow to 438 million people by 2030, corresponding to 7.8% of the adult population.

Robert deZanger, CEO of Natures Bioceuticals stated "The purchase of this formula is a major coup for our company. The inventor, a type 2 diabetic, originally developed the formula to treat his personal condition. After taking the formula for a short period of time his blood sugar levels were consistently in the normal range. He stopped taking the formula after about six months and approximately nine months later his blood sugar level still remains in the normal range.  This product could be as big, if not bigger, that our Breathing Formula. Obviously, the potential of this product is enormous. It is our intention to immediately commence a clinical study encompassing both type 1 and type 2 diabetics to document the results achieved. During this period we will be formulating our marketing strategy. We intend to discuss possible joint ventures with major companies that have the financial resources to fund the drug approval process with the FDA. This process could take ten years and 200-300 million dollars. However, as this is an all natural product containing ingredients that are generally regarded as safe (GRAS), we also have the option to bring the product to market immediately as a dietary supplement under the Dietary Supplement Health and Education Act of 1994 (DSHEA). This would limit our ability to make claims about treating diabetes as only an FDA approved drug can make such claims.  Because of the vast potential of this formula and the infancy of our marketing plan it is hard to quantify the revenue potential for this product but as a guesstimate we feel that year one revenues, if sold as a supplement, could exceed $10,000,000.00 the first year."

About Nature's Bioceuticals:

Nature's Bioceuticals develops and acquires the rights to natural medicine formulas that are geared towards treating specific medical conditions. These medicines are all natural and derived from botanicals and mineral bases. Nature's Bioceuticals strives to provide high quality natural medicines that are as effective, if not more effective, than synthetic drugs and more importantly do not have the negative side effects usually associated with many of today's prescribed drugs.

Nature's line of natural medicines will be either sold as prescription drugs, if applied for by the company and approved by the FDA, or sold as dietary supplements under the Dietary Supplement Health and Education Act of 1994, commonly referred to as "DSHEA"

In addition to historical information, this release contains forward-looking statements.

Mistral Ventures, Inc. and/or Nature's Bioceuticals may, from time to time, make written or oral forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements encompass Mistral Ventures, Inc. and/or Nature's Bioceuticals beliefs, expectations, hopes, or intentions regarding future events. Words such as "expects," "intends," "believes," "anticipates," "should," "likely," and similar expressions identify forward-looking statements. All forward-looking statements included in this release are made as of the date hereof and are based on information available to the Company as of such date. Neither Mistral Ventures, Inc. nor Nature's Bioceuticals assume any obligation to update any forward-looking statement. Actual results will vary, and may vary materially, from those anticipated, estimated, projected or expected for a number of reasons, including, among others: further reviews of the Company's financial statements by the Company and its Audit Committee; modification of the Company's accounting practices; foreign business risks; industry cyclicality; fluctuations in customer demand and order pattern; changes in pricing and general economic conditions; as well as other risks that may be delineated from time to time or filed with the SEC.

Media Contact:
Financial Insights
Phone Number: 888 656 3509
E-mail: [email protected]
www.naturesbioceuticals.com

SOURCE Nature's Bioceuticals

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED